BCR-ABL, Tyrosine Kinase Inhibitor Response

See Cepmed’s Personalized Medicine Portal for more information about this test

Read More

Select your province to learn about access to testing & services in your area.

Overview

Tyrosine kinase inhibitors imatinib (Gleevec®),  dasatinib (Sprycel®) and  nilotinib (Tasigna®) are used to treat Philadephia (Ph) chomosome positive or BCR-ABL positive, chonic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).  Molecular testing is used to determine if the leukemia cells are Ph chomosome or BCR-ABL positive. Follow the Read More button above to learn more.

This type of testing is available through regional genetics centres and cancer centres and paid for by provincial health care plans.  Discuss this test with your physician if you feel it could be beneficial for you.

Public Providers

Resources

Private Laboratories

*U.S. laboratories listed are certified by Centers for Medicare & Medicaid Service (CMS) CLIA Program

Overview

Tyrosine kinase inhibitors imatinib (Gleevec®),  dasatinib (Sprycel®) and  nilotinib (Tasigna®) are used to treat Philadephia (Ph) chomosome positive or BCR-ABL positive, chonic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).  Molecular testing is used to determine if the leukemia cells are Ph chomosome or BCR-ABL positive. Follow the Read More button above to learn more.

This type of testing is available through regional genetics centres and cancer centres and paid for by provincial health care plans.  Discuss this test with your physician if you feel it could be beneficial for you.

Public Providers

Resources

Private Laboratories

*U.S. laboratories listed are certified by Centers for Medicare & Medicaid Service (CMS) CLIA Program

Overview

Tyrosine kinase inhibitors imatinib (Gleevec®),  dasatinib (Sprycel®) and  nilotinib (Tasigna®) are used to treat Philadephia (Ph) chomosome positive or BCR-ABL positive, chonic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).  Molecular testing is used to determine if the leukemia cells are Ph chomosome or BCR-ABL positive. Follow the Read More button above to learn more.

This type of testing is available through regional genetics centres and cancer centres and paid for by provincial health care plans.  Discuss this test with your physician if you feel it could be beneficial for you.

Public Providers

Resources

Private Laboratories

*U.S. laboratories listed are certified by Centers for Medicare & Medicaid Service (CMS) CLIA Program

Overview

Tyrosine kinase inhibitors imatinib (Gleevec®),  dasatinib (Sprycel®) and  nilotinib (Tasigna®) are used to treat Philadephia (Ph) chomosome positive or BCR-ABL positive, chonic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).  Molecular testing is used to determine if the leukemia cells are Ph chomosome or BCR-ABL positive. Follow the Read More button above to learn more.

This type of testing is available through regional genetics centres and cancer centres and paid for by provincial health care plans.  Discuss this test with your physician if you feel it could be beneficial for you.

Public Providers

Resources

Private Laboratories

*U.S. laboratories listed are certified by Centers for Medicare & Medicaid Service (CMS) CLIA Program

Overview

Tyrosine kinase inhibitors imatinib (Gleevec®),  dasatinib (Sprycel®) and  nilotinib (Tasigna®) are used to treat Philadephia (Ph) chomosome positive or BCR-ABL positive, chonic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).  Molecular testing is used to determine if the leukemia cells are Ph chomosome or BCR-ABL positive. Follow the Read More button above to learn more.

This type of testing is available through regional genetics centres and cancer centres and paid for by provincial health care plans.  Discuss this test with your physician if you feel it could be beneficial for you.

Public Providers

Resources

Private Laboratories

*U.S. laboratories listed are certified by Centers for Medicare & Medicaid Service (CMS) CLIA Program

Overview

Tyrosine kinase inhibitors imatinib (Gleevec®),  dasatinib (Sprycel®) and  nilotinib (Tasigna®) are used to treat Philadephia (Ph) chomosome positive or BCR-ABL positive, chonic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).  Molecular testing is used to determine if the leukemia cells are Ph chomosome or BCR-ABL positive. Follow the Read More button above to learn more.

This type of testing is available through regional genetics centres and cancer centres and paid for by provincial health care plans.  Discuss this test with your physician if you feel it could be beneficial for you.

Public Providers

Resources

Private Laboratories

*U.S. laboratories listed are certified by Centers for Medicare & Medicaid Service (CMS) CLIA Program

Overview

Tyrosine kinase inhibitors imatinib (Gleevec®),  dasatinib (Sprycel®) and  nilotinib (Tasigna®) are used to treat Philadephia (Ph) chomosome positive or BCR-ABL positive, chonic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).  Molecular testing is used to determine if the leukemia cells are Ph chomosome or BCR-ABL positive. Follow the Read More button above to learn more.

This type of testing is available through regional genetics centres and cancer centres and paid for by provincial health care plans.  Discuss this test with your physician if you feel it could be beneficial for you.

Public Providers

Resources

Private Laboratories

*U.S. laboratories listed are certified by Centers for Medicare & Medicaid Service (CMS) CLIA Program

Overview

Tyrosine kinase inhibitors imatinib (Gleevec®),  dasatinib (Sprycel®) and  nilotinib (Tasigna®) are used to treat Philadephia (Ph) chomosome positive or BCR-ABL positive, chonic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).  Molecular testing is used to determine if the leukemia cells are Ph chomosome or BCR-ABL positive. Follow the Read More button above to learn more.

This type of testing is available through regional genetics centres and cancer centres and paid for by provincial health care plans.  Discuss this test with your physician if you feel it could be beneficial for you.

Public Providers

Resources

Private Laboratories

*U.S. laboratories listed are certified by Centers for Medicare & Medicaid Service (CMS) CLIA Program

Overview

Tyrosine kinase inhibitors imatinib (Gleevec®),  dasatinib (Sprycel®) and  nilotinib (Tasigna®) are used to treat Philadephia (Ph) chomosome positive or BCR-ABL positive, chonic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).  Molecular testing is used to determine if the leukemia cells are Ph chomosome or BCR-ABL positive. Follow the Read More button above to learn more.

This type of testing is available through regional genetics centres and cancer centres and paid for by provincial health care plans.  Discuss this test with your physician if you feel it could be beneficial for you.

Public Providers

Resources

Private Laboratories

*U.S. laboratories listed are certified by Centers for Medicare & Medicaid Service (CMS) CLIA Program

Overview

Tyrosine kinase inhibitors imatinib (Gleevec®),  dasatinib (Sprycel®) and  nilotinib (Tasigna®) are used to treat Philadephia (Ph) chomosome positive or BCR-ABL positive, chonic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).  Molecular testing is used to determine if the leukemia cells are Ph chomosome or BCR-ABL positive. Follow the Read More button above to learn more.

This type of testing is available through regional genetics centres and cancer centres and paid for by provincial health care plans.  Discuss this test with your physician if you feel it could be beneficial for you.

Public Providers

Resources

Private Laboratories

*U.S. laboratories listed are certified by Centers for Medicare & Medicaid Service (CMS) CLIA Program